Squamous Cell Cancer

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery

Using MC1R Genotype to Impact Melanoma Risk Behavior

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions.

Study to Examine Lesions of the Skin Using Confocal Laser Microscopy

Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer

Zalutumumab in Non-curable Patients With SCCHN

Safety Study of SEA-CD40 in Cancer Patients

Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study

PET-CT for Squamous Cell Carcinoma (SCC) of the Neck Nodes Unknown Primary Malignancy

Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer

Study of Sorafenib/Cetuximab in Head and Neck Cancer

Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)